The Gut Microbiome Correlated to Chemotherapy Efficacy in Diffuse Large B-Cell Lymphoma Patients

被引：5
|
作者：
Xu, Zhuo-Fan [1 ,2 ]
Yuan, Li [1 ]
Zhang, Yan [1 ]
Zhang, Wei [1 ]
Wei, Chong [1 ]
Wang, Wei [1 ]
Zhao, Danqing [1 ]
Zhou, Daobin [1 ,3 ]
Li, Jingnan [4 ]
机构：
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Hematol, Beijing 100005, Peoples R China
[2] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China
[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, State Key Lab Complex Severe & Rare Dis, Beijing 100005, Peoples R China
[4] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Gastroenterol, Beijing 100005, Peoples R China
来源：
HEMATOLOGY REPORTS | 2024年 / 16卷 / 01期
基金：
中国国家自然科学基金;
关键词：
diffuse large B-cell lymphoma; gut microbiota; 16S rRNA; metagenomic sequencing; Proteobacteria; BACTERIA; STRESS; GENE;
D O I：
10.3390/hematolrep16010007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The gut microbiome (GMB) has been extensively reported to be associated with the development and prognosis of human diseases. This study aims to investigate the relationship between GMB composition and chemotherapy efficacy in diffuse large B-cell lymphoma (DLBCL). We demonstrated that DLBCL patients at diagnosis have altered GMB compositions. Significant enrichment of the Proteobacteria phylum in DLBCL patients was observed. Gene analysis showed a high abundance of virulence factors genes. We found baseline GMB to be associated with clinical outcomes. The emergence of Lactobacillus fermentum was correlated with better treatment outcome. Our pilot results suggested a correlation between GMB composition and DLBCL development and prognosis. Clues from our study, together with previous research, provided a rational foundation for further investigation on the pathogenesis, prognosis value, and targeted therapy of GMB in DLBCL.
引用
收藏
页码：63 / 75
页数：13
相关论文
共 50 条
  • [1] The gut microbiota is altered significantly in primary diffuse large b-cell lymphoma patients and relapse refractory diffuse large b-cell lymphoma patients
    Xu, Yu
    Shi, Chang
    Qian, Jiejing
    Yu, Xiao
    Wang, Shasha
    Shao, Li
    Yu, Wenjuan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [2] Rituximab and chemotherapy in diffuse large B-cell lymphoma
    Sonet, Anne
    Bosly, Andre
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 719 - 726
  • [3] DIFFUSE LARGE B-CELL LYMPHOMA IN GLIOMA PATIENTS TREATED WITH TEMOZOLOMIDE CHEMOTHERAPY
    Cordera, S.
    Bottacchi, E.
    Alvaro, M.
    Joossens, E.
    Neyns, B.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1119 - 1120
  • [4] The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma
    Arkenau, H. -T.
    Chong, G.
    Cunningham, D.
    Watkins, D.
    Agarwal, R.
    Sirohi, B.
    Trumper, M.
    Norman, A.
    Wotherspoon, A.
    Horwich, A.
    ANNALS OF ONCOLOGY, 2007, 18 (03) : 541 - 545
  • [5] Diffuse large B-cell lymphoma - Molecular heterogeneity of diffuse large B-cell lymphoma
    Gascoyne, RD
    HEMATOLOGY JOURNAL, 2004, 5 : S144 - S148
  • [6] Chemotherapy Alone for Localized Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    CANCER JOURNAL, 2012, 18 (05): : 421 - 426
  • [7] Results of CHOP chemotherapy for diffuse large B-cell lymphoma
    Hallack Neto, A. E.
    Pereira, J.
    Beitler, B.
    Chamone, D. A. F.
    Llacer, P. D.
    Dulley, F. L.
    Macedo, M. C. M. A.
    Chaoubah, A.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2006, 39 (10) : 1315 - 1322
  • [8] Efficacy of RCDOP regimen in the treatment of patients with diffuse large B-cell lymphoma
    曹怡文
    China Medical Abstracts(Internal Medicine), 2018, 35 (03) : 187 - 187
  • [9] Efficacy Of Rituximab To Chemotherapy In The Treatment Of EBV-Positive Diffuse Large B-Cell Lymphoma
    Beltran, Brady E.
    Chavez, Julio C.
    Castillo, Jorge J.
    BLOOD, 2013, 122 (21)
  • [10] DeVIC chemotherapy is effective for patients with refractory or relapsed diffuse large B-cell lymphoma
    Okada, Kazuya
    Sakai, Kazuya
    Muranushi, Hiroyuki
    Okamoto, Yusuke
    Sugiura, Hiroyuki
    Sato, Aki
    Sato, Takayuki
    Maeda, Takeshi
    Onishi, Tatsuhito
    Ueda, Yasunori
    ANNALS OF ONCOLOGY, 2015, 26 : 108 - 108
12345